Gilead reported 13% third-quarter product sales growth and 3% non-GAAP diluted earnings per share growth. Management increased 2026 product sales guidance by $900 million at the midpoint based on HIV product outperformance and forecast a steeper non-GAAP EPS decline, largely due to acquisitions.
Gilead markets several single-tablet regimens for HIV, and its next-generation products with better long-term safety profiles, led by Biktarvy, are boosting the company's market share.
Gilead's Yeztugo is a promising new HIV prevention drug, but it is unclear if markets outside the US will embrace this form of therapy.
|
Metric
|
GILD
|
ABBV
|
MRK
|
|---|---|---|---|
Price/Earnings (Normalized) | — | 32.94 | 123.91 |
Price/Book Value | 16.61 | — | 8.85 |
Price/Sales | 7.01 | 7.92 | 5.52 |
Price/Cash Flow | 14.73 | 22.24 | 16.84 |
|
Metric
|
GILD
|
ABBV
|
MRK
|
|---|---|---|---|
Quick Ratio | 0.95 | 0.56 | 0.71 |
Current Ratio | 1.38 | 0.87 | 1.32 |
Interest Coverage | −1.78 | 5.20 | 4.28 |
|
Metric
|
GILD
|
ABBV
|
MRK
|
|---|---|---|---|
Return on Assets (Normalized) | −0.60% | 16.61% | 6.27% |
Return on Equity (Normalized) | −1.77% | — | 16.68% |
Return on Invested Capital (Normalized) | 0.51% | 36.97% | 9.74% |
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Eli Lilly and Co
LLY
| LOCK|gYP!<CP | LOCK|?& | $1T | |||
| Johnson & Johnson
JNJ
| LOCK|jhtF<L | LOCK|R$! | $641B | |||
| AbbVie Inc
ABBV
| LOCK|dTT>V$ | LOCK|y$% | $506B | |||
| Roche Holding AG ADR
RHHBY
| LOCK|?@nWwNcp | LOCK|@C^ | $382B | |||
| Merck & Co Inc
MRK
| LOCK|kY$hGt@ | LOCK|hB | $357B | |||
| Novartis AG ADR
NVS
| LOCK|W&<>#^## | LOCK|@C | $303B | |||
| AstraZeneca PLC
AZN
| LOCK|%&bS$NK | LOCK|<#$ | $286B | |||
| Amgen Inc
AMGN
| LOCK|?t%s?>< | LOCK|hvy | $249B | |||
| Novo Nordisk AS ADR
NVO
| LOCK|$mLTsq | LOCK|X& | $178B |
United States